Inhibition of AXL (via bemcentinib or MYD1-72) resensitizes ovarian cancer cells to platinum, ATR inhibitors (ATRis) and PARPis by increasing DNA damage and inducing RS [130–132]. Here, AXL is linked to ovarian carcinoma.